GLOBAL BIOLIFE, INC. – Trademark Portfolio

Entity Type: 03

GLOBAL BIOLIFE, INC. holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 5 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 3 Nice Classification classes. Currently, 0 trademarks are registered and 3 are pending. The owner is based in Bethesda, MD.

Suite 210

4800 Montgomery Lane

Bethesda, MD 20814

7 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

3F
3F
Pending 2025
EQUIVIR
EQUIVIR
Pending 2022
3F
3F
Abandoned 2022
3F
3F
Abandoned 2021
LAETOSE
LAETOSE
Abandoned 2017
3F
3F
Abandoned 2017

Trademark Classifications

GLOBAL BIOLIFE, INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (5 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

3
Cosmetics & Cleaning (3 filings)

Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring

1
Chemicals (1 filing)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

Frequently Asked Questions

How many trademarks does GLOBAL BIOLIFE, INC. have?

GLOBAL BIOLIFE, INC. has 7 U.S. trademarks filed with the USPTO. Of these, 3 pending, 4 abandoned.

What trademark classes does GLOBAL BIOLIFE, INC. file in?

GLOBAL BIOLIFE, INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning), Class 1 (Chemicals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What is GLOBAL BIOLIFE, INC.'s trademark registration success rate?

GLOBAL BIOLIFE, INC. has a 0% trademark registration rate, with 0 out of 4 resolved applications resulting in successful registration. Currently, 3 applications are pending review.